



Novo Nordisk in Washington State

Novo Nordisk's Research Center in Seattle is the epicenter of Novo Nordisk's research activities in the US. The unique concept behind the center is to combine basic research, early proof-of-concept trials and medical device research under one umbrella. Researchers have a mandate to pursue a translational research approach to finding new antigen-based immunological and vaccine treatment advances for type 1 diabetes and obesity, and to identify game changing devices to support treatments.

OUR FACILITIES

Established in 2009, the research center is focused on early discovery projects within the diabetes and obesity areas. Our scientists apply cutting edge technologies to bring molecules to market. Right now, that means identifying protein-based therapies for obesity and prevention of diabetes, and diabetes treatment as well as research on the next generation of medical devices.

ECONOMIC IMPACT

Drawn to Seattle for the city's reputation as a biotech hub, Novo Nordisk has invested over \$200 million in the region since 2009. The center currently employs over 120 people.

IN THE COMMUNITY

Novo Nordisk is committed to making a difference in Seattle through support for local organizations and partnerships with the Seattle biotech and academic communities that focus on early-stage research projects. Currently, we partner with the University of Washington, the Pacific Northwest Diabetes Research Institute, and the Benaroya Research Institute on projects such as long-term autoimmune disorders studies. We are also working with JDRF to accelerate discovery and development of novel immunotherapies to prevent, treat and cure type 1 diabetes. Additionally, we sponsor Shoreline Community College's biotechnology program and participate in the City of Seattle's youth employment program.

About Novo Nordisk

Novo Nordisk is a global health care company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: hemophilia, growth disorders and obesity. With US headquarters in Plainsboro, NJ, Novo Nordisk Inc. has nearly 5,000 employees in the United States. For more information, visit novonordisk.us or follow us on Twitter: [@novonordiskus](https://twitter.com/novonordiskus).



FAST FACTS



APPROXIMATELY **120** EMPLOYEES



ESTABLISHED IN **2009**



SITE MILESTONES

- 2012: Establishment of Type 1 Diabetes Research Team
- 2014: Establishment of Obesity Research Team
- 2015: Establishment of Protein Engineering Team
- 2015: Establishment of Device Research Team
- 2016: Acquisition of an additional 30,000 square feet
- 2016: Completion of new Protein and Peptide Chemistry lab



AWARDS AND RECOGNITIONS

- Seattle Business Magazine "Best Places to Work"
- Puget Sound Business Journal "BizzCycle Gold Certificate"
- League of American Bicyclists "Gold Certificate"
- Seattle Cascade Bicycle Club Participant
- Governor's Life Sciences Council Participant
- City of Seattle's Youth Employment Program Participant



SUPPLIER RELATIONS WITH **260 VENDORS**, 54 OF WHICH ARE CLASSIFIED AS:

- Female-owned
- Veteran-owned
- Minority-owned



SINCE ESTABLISHED, MORE THAN **\$6 MILLION** IN WAGE AND REAL ESTATE TAXES PAID

Washington State Location

Novo Nordisk Research Center Seattle, Inc.
500 Fairview Avenue
Seattle, WA 98109
(206) 490-5700